Wockhardt Ltd. has begun the new year on a disappointing note after a US FDA warning letter referred to a range of current good manufacturing practice (CGMP) violations at the firm’s Ankleshwar site in India, including those around data integrity.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?